ProCE Banner Activity

GRAALL-R: Adding Rituximab to Chemotherapy Prolongs Event-Free Survival in CD20+, Ph-, B-Cell Precursor ALL

Slideset Download
Conference Coverage
Results of a phase III trial investigating the addition of rituximab to chemotherapy in B-cell ALL.

Released: December 08, 2015

Expiration: December 06, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen